

Product Information

MS-SAFE Protease and Phosphatase Inhibitor

Mass Spectrometry Safe Protease and Phosphatase Inhibitor Cocktail

MSSAFE

Product Description

Crude cell extracts contain a myriad of endogenous enzymes, such as proteases and phosphatases, which can degrade or modify the proteins present in the sample. The best way to preserve the integrity of the proteins is to add a broad spectrum of protease and phosphatase inhibitors tailored to the sample and task.

MS-SAFE is a mass spectrometry-compatible, general purpose protease and phosphatase inhibitor cocktail. The protease inhibitors in MS-SAFE have broad specificity for the inhibition of serine, cysteine, aspartic, and metalloproteases. The phosphatase inhibitors in MS-SAFE act upon tyrosine, serine/threonine, acid and alkaline phosphatases. MS-SAFE contains a unique formulation, including a pepstatin A salt, to provide additional protection not normally obtained in a cocktail format.

All inhibitors, plus the fillers, were selected so as not to interfere with LC-MS analyses. Any inhibitors capable of covalent, irreversible protein modification were avoided. For example, 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), a commonly used potent serine protease inhibitor, has been demonstrated to modify non-target proteins, and thus introduce artifacts in mass spectral interpretation.¹ Therefore, AEBSF is not used in MS-SAFE.

MS-SAFE is EDTA-free. All inhibitors were selected to allow facile downstream sample processing, such as immobilized metal affinity chromatography (IMAC) for His-tagged protein purification and, uniquely, phosphopeptide enrichment. Of note, most phosphatase inhibitor cocktails contain glycerophosphate, molybdate, or other compounds known to compromise phosphopeptide enrichment using iron, gallium, or titanium dioxide-based affinity matrices.²

MS-SAFE has been tested in mammalian cell lysates and liver tissue extracts. Several theses¹² and dissertations¹³⁻²⁷ have cited use of product MS-SAFE in their research protocols.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

Vials of MS-SAFE powder are stable, as supplied, for at least 2 years at 2-8 °C.

A 10× concentrated solution of MS-SAFE was tested and found to be stable for 16 hours on ice, or for 4 days when stored frozen at -20 °C. Avoid repeated freeze/thaw cycles of the frozen 10× solution.

Components

Each vial of MS-SAFE can be used to prepare 20 mL of 1× inhibitor solution, which contains the following inhibitors. Inhibitory targets of the components are shown:

- Bestatin hydrochloride (Cat. No. B8385): aminopeptidases, such as leucine aminopeptidase and alanyl aminopeptidase^{3,4}
- Leupeptin (Cat. No. L2884): serine and cysteine proteases, such as trypsin, plasmin, trypsinogen, urokinase, and kallikrein^{3,4}
- Phosphoramidon disodium salt (Cat. No. R7385): thermolysin and collagenase³
- Pepstatin A (Cat. No. P5318): acid proteases, such as pepsin, renin, and cathepsin D, and many microbial aspartic proteases³
- Elastatinal (Cat. No. E0881): elastase^{3,4}

- Aprotinin (Cat. No. A3428): serine proteases, such as chymotrypsin, trypsin, and elastase^{5,6}
- Nafamostat mesylate (Cat. No. N0289): serine proteases, kallikrein
- Antipain (Cat. No. A6191): serine/cysteine proteases and some trypsin-like serine proteases³
- Okadaic Acid (Cat. No. O7885): type 2A protein phosphatases⁸
- Sodium Fluoride (Cat. No. S7920): serine and threonine phosphatases⁹
- Sodium Orthovanadate (Cat. No. S6508): ATPases, protein tyrosine phosphatases and other phosphate-transferring enzymes¹⁰
- Bromotetramisole Oxalate (Cat. No. 190047): L-isoforms of alkaline phosphatases¹¹

β-Lactose & DL-Leucine are added as filler.

Preparation Instructions

A 1× working solution of MS-SAFE is prepared by adding 20 mL of extraction/lysis buffer to one vial of powder.

Alternatively, a 10× concentrated solution of MS-SAFE may be prepared by adding 2 mL of water or extraction/lysis buffer to one vial of powder. This 10× solution may then be diluted 10-fold into extraction/lysis buffer as needed for a 1× working solution.

Prior to use, the 1× or 10× solution should be mixed (15 minutes) until dissolved. Concentrations greater than 1× may appear slightly hazy. This will not affect the performance of the inhibitors.

Procedure

MS-SAFE has been tested for inhibition of proteases and phosphatases in mammalian samples. 20 mL of a 1× working solution of MS-SAFE in CellLytic™ M (Cat. No. C2978) mammalian cell lysis buffer will inhibit proteases and phosphatases present in a HeLa cell extract prepared from 2×10^8 cells (60 mg total protein by BCA). 20 mL of a 1× MS-SAFE working solution will inhibit proteases and phosphatases in the extract from 15 mg of rat liver.

Since all organisms will contain different types and amounts of endogenous proteases and phosphatases, it may be necessary first to test MS-SAFE for effectiveness in non-mammalian samples.

References

1. Schuchard, M.D. *et al.*, *BioTechniques*, **39(2)**, 239-247 (2005).
2. Aryal, U.K., and Ross, A.R.S., *Rapid Commun. Mass Spectrom.*, **24(2)**, 219-231 (2010).
3. Umezawa, H., *Ann. Rev. Microbiol.*, **36**, 75-99 (1982).
4. Mumford, R.A. *et al.*, *Biochem. Biophys. Res. Comm.*, **103(2)**, 565-572 (1981).
5. Fritz, H., and Wunderer, G., *Arzneimittelforschung (Drug Research)*, **33(4)**, 479-494 (1983).
6. Hewlett, G., *Bio/Technology*, **8**, 565-568 (1990).
7. Fujii, S. *et al.*, *Biochim. Biophys. Acta*, **661(2)**, 342-345 (1981).
8. Bialojan, C. *et al.*, *Biochem. J.*, **256(1)**, 283-290 (1988).
9. Jaumot, M. *et al.*, *Oncogene*, **20(30)**, 3949-3958 (2001).
10. Huyer, G. *et al.*, *J. Biol. Chem.*, **272(2)**, 843-851 (1997).
11. Metaye, T. *et al.*, *Biochem. Pharm.*, **37(22)**, 4263-4268 (1988).
12. Pouv, Amara K., "Molecular interactions of environmental chemicals with tuna and honeybee xenobiotic defense transporter P-glycoprotein: Using ligand-binding site conservation to predict chemical bioaccumulation". University of California Davis, M.S. thesis, p. 86 (2021).
13. Chemonges, Saul, "Development of a novel encyclopaedic peptide spectral library using the liquid fraction of sheep blood". University of Queensland, Ph.D. dissertation, p. 30 (2017).
14. Ghoshdastidar, Shreya, "Clinical Translation of Nanomaterials for Early Detection of Genetic Abnormalities in Fetus and Retinopathy in Neonates and Adults". University of Missouri Columbia, Ph.D. dissertation, pp. 11, 18 (2017).
15. Simpson, Kingsley, "The Roles of Factor XIII-A and Transglutaminase 2 in the Vasculature". University of Leeds, Ph.D. dissertation, p. 73 (2017).
16. Krga, Irena S., "Effects of anthocyanins and their metabolites on the function of human endothelial cells and platelets *in vitro*". University of Belgrade/University of Clermont Auvergne, Ph.D. dissertation, pp. 38, 57 (2018).

MILLIPORE
SIGMA

17. Al-Omari, Abdullah, "Identification of distinct markers to differentiate natural and induced T regulatory cells in cancer". Nottingham Trent University, Ph.D. dissertation, pp. 136, 140, 142 (2019).
18. Began, Jakub, "Rhomboid family intramembrane proteases in prokaryotes: mechanism, substrate repertoires and biological functions in the Gram-positive bacterium *Bacillus subtilis*". Charles University (Prague), Ph.D. dissertation, pp. 32, 40 (2019).
19. Blackburn, Brian K., "Receptor for Advanced Glycation End Products Mediates NADPH Oxidase Signaling in Human Skeletal Muscle". University of Illinois at Chicago, Ph.D. dissertation, p. 87 (2019).
20. Chapman, Gareth David, "Modelling of Neurodevelopmental Disorders Associated with 1q21.1 deletion and duplication using human iPSCs". Cardiff University, Ph.D. dissertation, p. 44 (2019).
21. Ibrahim, Shaimaa I.A., "Characterization of the Glucocorticoid Receptor in a rat model of low back pain". University of Cincinnati, Ph.D. dissertation, p. 39 (2019).
22. Kuil, Laura Esmee, "Genetics of Tissue Macrophage Development and Function: From zebrafish to human disease". Erasmus Universiteit Rotterdam, Ph.D. dissertation, p. 113 (2019).
23. Montone, Carmela Maria, "Bioactive compounds analysis in food matrices and waste products". Sapienza Università di Roma, Ph.D. dissertation, p. 83 (2019).
24. Heilmann, Geronimo, "The use of mass-spectrometry-based chemical proteomics approaches in bioactivity annotation of natural products and biocatalyst discovery: Applications to the natural product Zelkovamycin and fungi". University of Duisberg-Essen, Dr. rer. nat. dissertation, Appendix, p. viii (2020).
25. Jaminon, Armand Mario Gerard, "Key role for VSMCs in vascular remodeling and calcification". Universiteit Maastricht, Ph.D. dissertation, p. 52 (2020).
26. Stremersch, Stephan, "Exploring extracellular vesicles for siRNA delivery and Raman-based diagnostics". Universiteit Gent, Pharm.D. dissertation, pp. 131, 170 (2020).
27. Thomas, Emma Louisa, "Protein processing in *Nicotiana benthamiana* by Vacuolar Processing Enzymes and other proteases". University of Oxford, Ph.D. dissertation, p. 76 (2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice).

Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://www.sigmaaldrich.com/terms).

Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.
© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

MSSAFEBul Rev 03/22 JGD,CMK,GCY,MAM,PHC

**MILLIPORE
SIGMA**